J07BX04 - Dengue Virus Vaccines |
Propably not porphyrinogenic |
PNP |
Rationale
Based on the pharmacokinetics of the dengue virus vaccine, no porphyrinogenic effects are expected.
Chemical description
Live attenuated virus vaccine.
Therapeutic characteristics
Indicated for protection against dengue disease. The vaccine can be given to adults, adolescents and children from 4 years of age. It is administered by a subcutaneous injection.
Metabolism and pharmacokinetics
Vaccines are not metabolized by the cytochrome P450 system.
Similar drugs
References
| # | Citation details | PMID |
|---|---|---|
| * | Government bodies | |
| 1. | European Medicines Agency (EMA). SmPC Qdenga.
|
|
| 2. | Norwegian institute of public health. Vaccines and vaccination.
|
|
Tradenames
Qdenga 
Dengvaxia · Qdenga 
Qdenga 
Qdenga 
Qdenga 
Qdenga 
Qdenga 
Dengvaxia · Qdenga 
Qdenga 
Dengvaxia · Qdenga 
Qdenga 
Dengvaxia · Qdenga 
Dengvaxia · Qdenga 
Dengvaxia · Qdenga 
Dengvaxia · Qdenga 
Dengvaxia · Qdenga 
Qdenga 
Qdenga 
Vaccines